Lead Product(s) : Eltanexor
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Eltanexor (KPT-8602/ATG-016) is an investigational novel SINE compound that functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus.
Brand Name : ATG-016
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2022
Lead Product(s) : Eltanexor
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Eltanexor
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Orphan drug designation received from FDA for ATG-016 (eltanexor), selective inhibitor of nuclear export compound on the basis of positive data from Phase 1 study which demonstrated 53% ORR and median overall survival of 9.9 months for the treatment of ...
Brand Name : ATG-016
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2022
Lead Product(s) : Eltanexor
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Eltanexor
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Karyopharm Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The National Medical Products Administration has approved the clinical trial of ATG-016 (eltanexor) in patients with intermediate and higher risk myelodysplastic syndrome according to the Revised IPSS-R after the failure of hypomethylating agents based t...
Brand Name : ATG-016
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 26, 2020
Lead Product(s) : Eltanexor
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Karyopharm Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?